Sopharma - Public Comps and Valuation Multiples

Sopharma Overview

About Sopharma

Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products; and Others. It generates the majority of its revenue from the Distribution of pharmaceutical products.

Founded

1933

HQ

Employees

4.7K+

Website

sopharmagroup.com

Sectors

Medical Supplies

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$810M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sopharma Financials

Sopharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Sopharma achieved revenue of $1.1B and an EBITDA of $103M.

Sopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sopharma valuation multiples based on analyst estimates

Sopharma P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$962M	$1.1B	XXX	XXX	XXX
Gross Profit	$197M	$206M	XXX	XXX	XXX
Gross Margin	21%	19%	XXX	XXX	XXX
EBITDA	$83.9M	$103M	XXX	XXX	XXX
EBITDA Margin	9%	9%	XXX	XXX	XXX
Net Profit	$51.8M	$42.0M	XXX	XXX	XXX
Net Margin	5%	4%	XXX	XXX	XXX
Net Debt	$138M	$103M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Sopharma Stock Performance

As of May 13, 2025, Sopharma's stock price is BGN 6 (or $4).

Sopharma has current market cap of BGN 1.1B (or $614M), and EV of BGN 1.4B (or $810M).

See Sopharma trading valuation data

Sopharma Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$810M	$614M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Sopharma Valuation Multiples

As of May 13, 2025, Sopharma has market cap of $614M and EV of $810M.

Sopharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Sopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Sopharma and 10K+ public comps

Sopharma Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$810M	XXX	XXX	XXX
EV/Revenue	0.7x	XXX	XXX	XXX
EV/EBITDA	7.9x	XXX	XXX	XXX
P/E	11.1x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	802.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sopharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Sopharma Valuation Multiples

Sopharma's NTM/LTM revenue growth is n/a

Sopharma's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged n/a for the same period.

Over next 12 months, Sopharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Sopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Sopharma and other 10K+ public comps

Sopharma Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	13%	XXX	XXX	XXX	XXX
EBITDA Margin	N/A	XXX	XXX	XXX	XXX
EBITDA Growth	22%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	N/A	XXX	XXX	XXX	XXX
Revenue per Employee	$0.2M	XXX	XXX	XXX	XXX
Opex per Employee	n/a	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	0%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
Opex to Revenue	0%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial